The effect of erythropoietin on platelet and endothelial activation markers: A prospective trial in healthy volunteers

Platelets

Volumn 23, Issue 5, 2012, Pages 352-358

  Heinisch, Birgit B ^a   Vcelar, Brigitta ^b   Kapiotis, Stylianos ^c   Blann, Andrew ^d   Wolzt, Michael ^a   Siller Matula, Jolanta M ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c Hospital of the Divine Redeemer   (Austria)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Endothelium; Erythropoietin; Gender; Hypertension; Thrombosis

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; RECOMBINANT ERYTHROPOIETIN; THROMBOMODULIN; THROMBOXANE B2; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETICULOCYTE COUNT; THROMBOCYTE;

BIOLOGICAL MARKERS; BLOOD PLATELETS; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; PLATELET ACTIVATION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REFERENCE VALUES; YOUNG ADULT;

EID: 84863681324     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.631621     Document Type: Article

References (47)

1. Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol 2008;141(3): 287-297.
2. Wadhwa M, Thorpe R. Haematopoietic growth factors and their therapeutic use. Thromb Haemost 2008;99(5):863-873.
3. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95(9):2983-2989.
4. Klein E, Georges A, Brossaud J, Bosredon K, Bordenave L, Corcuff JB. Erythropoietin: Indications and measurement. Ann Biol Clin (Paris) 2009;67(5):505-515.
5. Jeong SK, Cho YI, Duey M, Rosenson RS. Cardiovascular risks of anemia correction with erythrocyte stimulating agents: Should blood viscosity be monitored for risk assessment? Cardiovasc Drugs Ther 2010;24(2):151-160.
6. Jilma B, Marsik C, Mayr F, Graninger MT, Taylor Jr FB, Ribel MC, Erhardtsen E, Handler S, Eichler HG. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002;72(4):403-410.
7. Derhaschnig U, Schweeger-Exeli I, Marsik C, Cardona F, Minuz P, Jilma B. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia. Platelets 2010;21(5):320-328.
8. Jilma-Stohlawetz P, Hergovich N, Homoncik M, Dzirlo L, Horvath M, Janisiw M, Panzer S, Jilma B. Impaired platelet function among platelet donors. Thromb Haemost 2001;86(3):880-886.
9. Jilma B, Eichler HG, Breiteneder H, Wolzt M, Aringer M, Graninger W, Röhrer C, Veitl M, Wagner OF. Effects of 17 beta-estradiol on circulating adhesion molecules. J Clin Endocrinol Metab 1994;79(6):1619-1624.
10. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knobl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost 2010;104(3):563-570.
11. Owen EW, Roberts WL. Performance characteristics of a new Immulite(-) 2000 system erythropoietin assay. Clin Chim Acta 2011;412(5-6):480-482.
12. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R, Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) study. Nephrol Dial Transplant 2010;25(9):2846-2850.
13. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361(21):2019-2032.
14. Sayinalp N, Erdem Y, Ilhami Ozcebe O, Buyukasik Y, Caglar S, Dundar SV. Recombinant human erythropoietin increases platelet aggregation in chronic hemodialysis patients. Thromb Res 1998;90(4):195-198.
15. Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: A randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004;20(4):437-443.
16. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996;50(4):1255-1261.
17. Turi S, Soos J, Torday C, Bereczki C, Havass Z. The effect of erythropoietin on platelet function in uraemic children on haemodialysis. Pediatr Nephrol 1994;8(6):727-732.
18. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105(14):1650-1655.
19. Tang YD, Hasan F, Giordano FJ, Pfau S, Rinder HM, Katz SD. Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: Results of a double-blind, placebo-controlled, randomized trial. Am Heart J 2009;158(6):941-947.
20. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev 1992;72(2):449-489.
21. Cofta S, Wysocka E, Michalak S, Piorunek T, Batura- Gabryel H, Torlinski L. Endothelium-derived markers and antioxidant status in the blood of obstructive sleep apnea males. Eur J Med Res 2009;14(Suppl. 4):49-52.
22. de la Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens 2010;24(6):373-379.
23. Blann AD. Assessment of endothelial dysfunction: Focus on atherothrombotic disease. Pathophysiol Haemost Thromb 2003;33(5-6):256-261.
24. Matsumoto K, Fujishima K, Moriuchi A, Saishoji H, Ueki Y. Soluble adhesion molecule E-selectin predicts cardiovascular events in Japanese patients with type 2 diabetes mellitus. Metabolism 2010;59(3):320-324.
25. Allegra A, Buemi M, Corica F, Aloisi C, Frisina N. Erythropoietin administration induces an increase of serum levels of soluble E-selectin and soluble intercellular adhesion molecule 1. Nephron 1999;82(4):361-362.
26. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto Jr AM, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96(12):4219-4225.
27. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91(7):1914-1917.
28. Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, Amiral J, Richter V, Wagner OF. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 1999;159(3): 857-863.
29. Pernerstorfer T, Eichler HG, Stohlawetz P, Speiser W, Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men. Atherosclerosis 2001;155(2):389-393.
30. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years. Thromb Haemost 2006; 95(1):49-55.
31. Paulinska P, Spiel A, Jilma B. Role of von Willebrand factor in vascular disease. Hamostaseologie 2009;29(1):32-38.
32. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. von Willebrand factor and coronary heart disease: Prospective study and meta-analysis. Eur Heart J 2002;23(22):1764-1770.
33. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan- Vague I, et al. Endothelial cell markers and the risk of coronary heart disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004;109(11):1343-1348.
34. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: Focus on acute coronary syndromes. Circulation 2008;117(11):1449-1459.
35. Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb Res 2007;120(6):797-803.
36. Aguilera A, Selgas R, Ruiz-Caravaca ML, Bajo MA, Cuesta MV, Plaza MA, Hernanz A. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients. Perit Dial Int 1999;19(Suppl. 2):S161-S166.
37. Borawski J, Mysliwiec M. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin Appl Thromb Hemost 2002;8(1):77-84.
38. David-Dufilho M, Millanvoye-Van Brussel E, Topal G, Walch L, Brunet A, Rendu F. Endothelial thrombomodulin induces Ca2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II. J Biol Chem 2005;280(43):35999-36006.
39. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost 2003;1(7):1515-1524.
40. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, Amiral J, Midy D, Baste JC, Boisseau MR. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 1993;71(6):423-431.
41. Wu KK, Aleksic N, Ballantyne CM, Ahn C, Juneja H, Boerwinkle E. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation 2003;107(13):1729- 1732.
42. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT. Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 2001;159(3):797-802.
43. Wu KK. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol 2003;14(4):373-375.
44. Jilma B, Dirnberger E, Eichler HG, Kapiotis S. Sex differences in circulating P-selectin, E-selectin and thrombomodulin. Br J Haematol 1996;95(3):575-576.
45. Blann AD, Amiral J, McCollum CN. Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease. Br J Haematol 1996;95(2):263-265.
46. Strijbos MH, Rao C, Schmitz PI, Kraan J, Lamers CH, Sleijfer S, Terstappen LW, Gratama JW. Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. Thromb Haemost 2008;100(4): 642-647.
47. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, Rieger A, Wagner OF, Quehenberger P. Sex differences in HAART-associated dyslipidaemia. AIDS 2001;15(6):725-734.